<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828005</url>
  </required_header>
  <id_info>
    <org_study_id>OPNT003-PD-001</org_study_id>
    <nct_id>NCT04828005</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Evaluation of Intranasal Nalmefene</brief_title>
  <official_title>A Two-part Open Label Study of the Pharmacodynamic Effects of Intranasal Nalmefene Compared to Intranasal Naloxone in Healthy Volunteers Under Steady State Opioid Agonism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opiant Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Opiant Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the pharmacodynamics (the effects of the drug and mechanisms of&#xD;
      their action within the body) of Nalmefene when given intranasally (IN; into the nose)&#xD;
      compared to intranasal naloxone when given to healthy volunteers under steady state opioid&#xD;
      agonism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, 2-part study. Part 1 is a pilot study to determine the relationship between&#xD;
      opioid agonism and suppression of carbon dioxide induced increases in minute ventilation&#xD;
      prior to opioid exposure. Part 2 will be a randomized, 2 period, 2 treatment, crossover study&#xD;
      to evaluate the pharmacodynamic effects of intranasal (IN) nalmefene compared to IN naloxone&#xD;
      to reverse opioid-induced suppression of carbon dioxide induced increases in minute&#xD;
      ventilation, in healthy volunteers with prior opioid exposure.&#xD;
&#xD;
      Both Part 1 and Part 2 of the study will consist of an outpatient Screening Visit taking&#xD;
      place 28 days prior to admission, an in-clinic Treatment Phase consisting of a 6 or 7 day&#xD;
      inpatient stay, and a Follow-Up Phone Call conducted 3 to 7 days after discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in minute ventilation</measure>
    <time_frame>5 minutes</time_frame>
    <description>Change in minute ventilation from opioid induced nadir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum change in minute ventilation</measure>
    <time_frame>90 minutes</time_frame>
    <description>Maximum change in minute ventilation from opioid induced nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum change in minute ventilation</measure>
    <time_frame>90 minutes</time_frame>
    <description>Time to maximum change in minute ventilation from opioid induced nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minute ventilation</measure>
    <time_frame>90 minutes</time_frame>
    <description>Change in minute ventilation from opioid induced nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minute ventilation</measure>
    <time_frame>20 minutes</time_frame>
    <description>Change in minute ventilation from opioid induced nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minute ventilation</measure>
    <time_frame>15 minutes</time_frame>
    <description>Change in minute ventilation from opioid induced nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minute ventilation</measure>
    <time_frame>10 minutes</time_frame>
    <description>Change in minute ventilation from opioid induced nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minute ventilation</measure>
    <time_frame>2.5 minutes</time_frame>
    <description>Change in minute ventilation from opioid induced nadir</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pharmacodynamic</condition>
  <arm_group>
    <arm_group_label>Intranasal Nalmefene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nalmefene hydrochloride nasal spray, 3mg, 1 spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naloxone hydrochloride nasal spray, 4mg, 1 spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene hydrochloride</intervention_name>
    <description>3mg Nasal spray</description>
    <arm_group_label>Intranasal Nalmefene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone hydrochloride</intervention_name>
    <description>4mg Nasal Spray</description>
    <arm_group_label>Intranasal Naloxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 to 55 years inclusive&#xD;
&#xD;
          -  BMI ranging from 18 to 32 kg/m2, inclusive&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  Healthy subjects and non-dependent who are non dependent opioid experienced users,&#xD;
             opioid experience defined as exposure to an opioid on at least 1 occasion prior to&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant disease&#xD;
&#xD;
          -  Significant trauma injury, major surgery, open biopsy within 30 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Subject who has a difficult airway for intubation.&#xD;
&#xD;
          -  Following an abnormal diet 4 weeks prior to screening&#xD;
&#xD;
          -  Use of over-the-counter medications, dietary supplements, herbal products, vitamins or&#xD;
             opioid analgesics 14 days before intervention&#xD;
&#xD;
          -  Use of enzyme altering drugs 30 days before intervention&#xD;
&#xD;
          -  Use of nasal products 28 days before intervention and throughout the study&#xD;
&#xD;
          -  Previous or current opioid, alcohol, or other drug dependence&#xD;
&#xD;
          -  Donated or received blood 30 days before intervention&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding at screening&#xD;
&#xD;
          -  Women of childbearing potential unless surgically sterile or use effective&#xD;
             contraception&#xD;
&#xD;
          -  Current or recent upper respiratory tract infection&#xD;
&#xD;
          -  Allergic to nalmefene or naloxone or known hypersensitivity reaction to plastics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Searle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PRA Health Sciences</last_name>
    <phone>8018212156</phone>
    <email>info@opiant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PRA-EDS</last_name>
      <phone>801-821-2156</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Nalmefene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

